Neuphoria Therapeutics' CEO is Spyros Papapetropoulos, appointed in Jan 2023, has a tenure of 3.58 years. total yearly compensation is $951.34K, comprised of 57.8% salary and 42.2% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $37.67K. The average tenure of the management team and the board of directors is 3.1 years and 4.8 years respectively.
How has Spyros Papapetropoulos's remuneration changed compared to Neuphoria Therapeutics's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-US$17m
Dec 31 2025
n/a
n/a
-US$6m
Sep 30 2025
n/a
n/a
-US$9m
Jun 30 2025
US$951k
US$550k
-US$370k
Mar 31 2025
n/a
n/a
US$6m
Dec 31 2024
n/a
n/a
-US$8m
Sep 30 2024
n/a
n/a
-US$11m
Jun 30 2024
US$752k
US$525k
-US$15m
Mar 31 2024
n/a
n/a
-US$18m
Dec 31 2023
n/a
n/a
-US$20m
Sep 30 2023
n/a
n/a
-US$22m
Jun 30 2023
US$616k
US$321k
-US$21m
Compensation vs Market: Spyros's total compensation ($USD951.34K) is above average for companies of similar size in the US market ($USD655.15K).
Compensation vs Earnings: Spyros's compensation has increased whilst the company is unprofitable.
CEO
Spyros Papapetropoulos (53 yo)
3.6yrs
Tenure
US$951,343
Compensation
Dr. Spyridon Papapetropoulos, also known as Spyros, M. D., Ph. D., is Chief Development Officer & Strategic Advisor of Razor, Inc. He served as Chief Executive Officer at Neuphoria Therapeutics Inc. (forme...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Spyridon Papapetropoulos
Interim CEO
3.6yrs
US$951.34k
0.18% $ 37.7k
Timothy Cunningham
Chief Financial Officer
3.1yrs
US$254.36k
no data
Elizabeth Doolin
Senior Vice President of Clinical Development
2yrs
US$237.80k
no data
Julie Kerner
Senior Vice President of Business Operations
3.3yrs
no data
no data
Adrian Hinton
Financial Controller
3.1yrs
US$199.52k
no data
Rajeev Chandra
Company Secretary
no data
no data
no data
3.1yrs
Average Tenure
62.5yo
Average Age
Experienced Management: NEUP's management team is considered experienced (3.1 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Spyridon Papapetropoulos
Interim CEO
3.6yrs
US$951.34k
0.18% $ 37.7k
David Wilson
Independent Non-Executive Director
10.2yrs
US$91.06k
0.0022% $ 444.8
Alan Fisher
Independent Non-Executive Chair of the Board
9.9yrs
US$156.83k
0% $ 0
Jane Ryan
Independent Non-Executive Director
5.8yrs
US$84.58k
0.0043% $ 877.2
Srinivas Rao
Member of Clinical Advisory Board
4.8yrs
US$43.30k
no data
John Krystal
Member of Clinical Advisory Board
4.8yrs
no data
no data
Murray Stein
Member of Clinical Advisory Board
no data
no data
no data
Peter Miles Davies
Independent Non-Executive Director
5.1yrs
US$84.58k
0.0023% $ 479.8
Michael Gendreau
Member of Clinical Advisory Board
4.8yrs
no data
no data
Kimberly Smith
Director
less than a year
no data
no data
Stephen Doberstein
Director
less than a year
no data
no data
4.8yrs
Average Tenure
59.5yo
Average Age
Experienced Board: NEUP's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/12 11:25
End of Day Share Price
2026/08/12 00:00
Earnings
2026/03/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.